Disruption of adeB gene has a greater effect on resistance to meropenems than adeA gene in Acinetobacter spp. isolated from University Malaya Medical Centre. by Wong, E.W. et al.
Singapore Med J 2009; 50(8) : 822O r i g i n a l  A r t i c l e
Department 
of Medical 
Microbiology, 
Faculty of Medicine, 
University of Malaya, 
Kuala Lumpur 
50603,
Malaysia
Wong EW, PhD
Lecturer
Mohd Yusof  MY, 
MBBS
Associate Professor
Anbazhagan D, MSc 
PhD Student
Sekaran SD, PhD
Professor
Department of 
Anaesthesiology
Bt Mansor M, MBBS
Professor and Head
Ong SY, MBBS
Professor
Correspondence to:
Dr Shamala Devi 
Sekaran
Tel: (60) 3 7967 5759
Fax: (60) 3 7967 6672
Email: shamalamy@
yahoo.com
Disruption of adeB gene has a greater 
effect on resistance to meropenems 
than adeA gene in Acinetobacter spp. 
isolated from University Malaya Medical 
Centre
Wong E W, Mohd Yusof  M Y, Bt Mansor M, Anbazhagan D, Ong S Y, Sekaran S D
ABSTRACT 
Introduct ion :  The AdeABC pump of 
Acinetobacter spp. confers resistance to various 
antibiotic classes. This pump is composed of the 
AdeA, AdeB, and AdeC proteins where AdeB is 
a member of the resistance-nodulation-division 
efflux pump superfamily. The adeA, adeB, and 
adeC genes are contiguous and adjacent to adeS 
and adeR, which are transcribed in the opposite 
direction and which specify proteins homologous 
to sensors and regulators of two-component 
systems, respectively. In this study, an attempt is 
made to elucidate the role of the AdeABC efflux 
pump in carbapenem resistance in Acinetobacter 
spp. 
Methods : 39 carbapenem-resistant clinical 
isolates of Acinetobacter spp. were used. Minimum 
inhibitory concentrations were evaluated using 
the agar dilution method according to Clinical 
and Laboratory Standards Institute standards. 
The presence of carbapenem hydrolysing 
oxacillinases and AdeABC efflux pump genes were 
determined by PCR amplification. Subsequently, 
each gene was inactivated by plasmid insertion in 
order to study the contribution of these genes in 
developing antibiotic resistance and the resulting 
mutants were tested for their antimicrobial 
susceptibilities. 
Results : Among the multidrug-resistant 
strains, 36 strains had all the three (A, B, C) 
genes detected, while the remaining three 
strains had one or two of the genes detected. 
Inactivation of these individual genes showed 
decreased antimicrobial susceptibility indicating 
its contribution towards the development of 
antimicrobial resistance. 
Conclusion:  The presence of AdeABC multidrug 
efflux pump plays a major role in the development 
of antimicrobial resistance in Acinetobacter 
spp. The presence of either one or an interplay 
between these genes may have an effect on 
antimicrobial resistance in Acinetobacter spp.  
 
Keywords:  Acinetobacter spp., AdeABC efflux 
pump, antimicrobial resistance, carbapenam 
resistance, multidrug resistance 
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InTRODUCTIOn
Acinetobacter spp. are aerobic Gram-negative bacteria 
that are non-fermentative and are ubiquitous in the 
environment. This opportunistic pathogen can be 
involved in a range of nosocomial infections, including 
blood stream infections, meningitis, ventilator-associated 
pneumonia, wound and urinary tract infections. The 
emergence of antibiotic resistance among acinetobacters 
in hospitalised patients is a serious and recurrent problem 
for the treatment of infections.(1) Although carbapenems 
have been the most successful β-lactam antibiotics for 
the treatment of Acinetobacter spp. infections, there 
are increasing reports of carbapenem resistance among 
these pathogens.(2) There are several factors leading to 
carbapenem resistance in Acinetobacter spp. which include 
the ability of β-lactamases to hydrolyse carbapenems, 
the presence of metallo-β-lactamases, oxacillinases, 
mobile genetic elements, the reduced expression of 
outer membrane proteins (OMP) and penicillin-binding 
proteins.(3-5) AdeABC efflux pump-mediated antibiotic 
resistance includes resistance to aminoglycosides, β-
lactams, chloramphenicol, erythromycin, tetracyclines, 
and the dye ethidium bromide in Acinetobacter baumannii, 
and has been reported previously by Magnet et al.(6)
        The efflux system is a mechanism of antibiotic 
resistance involving the extrusion of toxic substrates from 
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within cells into the external environment with the help 
of transport proteins. In the bacteria kingdom, multidrug 
transporters can be divided into five major families; the 
major facilitator, the multidrug and toxic efflux, the small 
multidrug resistance, the ATP-binding cassette, and the 
resistance-nodulation-division (RND) superfamily.(7) The 
RND-type superfamily is the most commonly found efflux 
system in Gram-negative bacteria including Acinetobacter 
spp. The RND efflux transporters act as part of a tripartite 
system which includes a membrane fusion protein, and an 
OMP.(6) The AdeABC efflux pump belongs to the RND-
type superfamily which consists of adeA (membrane 
fusion), adeB (multidrug transporter), and adeC (outer 
membrane) genes. These three genes are contiguous, and 
adjacent to them are two-component regulatory systems, 
adeR and adeS, which are transcribed in the opposite 
direction.(8) The main aim of our study was to determine 
the role of AdeABC efflux pump genes in carbapenem 
resistance among the Acinetobacter spp. isolated from 
University Malaya Medical Centre, Kuala Lumpur, 
Malaysia. 
   
METhODS
39 isolates of carbapenem-resistant Acinetobacter spp. were 
obtained from patients who were hospitalised in University 
Malaya Medical Centre, Kuala Lumpur, Malaysia, from 
August 2003 to March 2004. These species were identified 
by the conventional method as described in the Manual 
of Clinical Microbiology(9) and the API20NE System 
(bioMérieux SA, Marcy-1’Etoile, France). Growth at 44°C 
was performed to differentiate between Acinetobacter 
baumannii and Acinetobacter calcoaceticus.(10) Further 
species level identification was done by amplified 
ribosomal DNA restriction analysis (ARDRA) as described 
by Koeleman et al.(11) Imipenem, meropenem, ceftazidime, 
cefotaxime, gentamicin, amikacin, ciprofloxacin and 
ampicillin (Oxoid, UK) susceptibility was tested by a disk 
diffusion method.(12) Minimum inhibitory concentrations 
(MICs) for the Acinetobacter spp. isolates were determined 
by an agar dilution method(13) and interpreted according 
to the guidelines of the Clinical Laboratory Standards 
Institute.(14)  The total genomic DNA was prepared using a 
standard boiling method by heating 2–5 colonies of bacteria 
suspension to 95°C for five minutes in a final volume of 50 
μL of distilled sterile water. After centrifugation at 13,000 
g, the suspensions were used as DNA templates. Plasmid 
DNA was extracted using the HiYieldTM Plasmid Mini Kit 
(Yeastern Biotech Co Ltd, Taiwan).
 Primers specific for blaOXA-23 were used to detect 
the presence of the blaOXA-23 gene encoding Class D β-
lactamases in Acinetobacter spp. as described by Alfaz-
Shah et al.(15) This amplification was performed using primer 
pairs 5’-GATGTGTCATAGTATTCGTCG-3’ (forward) 
and 5’-TCACAACAACTAAAAGCACTG-3’ (reverse). 
This set of primers gave an amplicon size of 1058 bp. The 
PCR reaction mixture in a final volume of 50 μL containing 
20 pmol (each) primer, 200 μM (each) deoxynucleotide 
triphosphate, 1 × reaction buffer, 1.5 mM MgCl2, 2.5 U 
Taq DNA polymerase (Fermentas, Lithuania, USA) and 
approximately 1 μL of template DNA was prepared. The 
master mix was then dispensed equally into each tube and 
vortexed. The tubes were then subjected to polymerase 
chain reaction (PCR) amplification using Thermal Cycler 
(BioRad, Hercules, USA). The thermocycling conditions 
used were: an initial denaturation step at 94°C for five 
minutes, followed by 25 cycles of denaturation at 94°C for 
25 s, annealing at 52°C for 40 s, elongation at 72°C for 50 s, 
followed by a final extension step at 72°C for six minutes.
 Primers of the adeA, adeB, adeC, adeR, and adeS were 
designed, and the forward and reverse primer sequences of 
all these genes are listed in Table I. Sma1 restriction sites 
were added to each forward and reverse primer sequences 
of each gene for ligation purposes. The presence of each 
gene was detected using Pfu DNA polymerase according 
to the manufacturers’ recommendations (Fermentas Inc, 
Lithuania). PCR mixes contained 1 μL of heat-extracted 
template DNA, 1 μL (20 pmol) of each primer and PCR 
premix containing 2.5 U of Taq DNA polymerase in a final 
volume of 50 μL. The thermocycle protocol used was: an 
initial denaturation step at 94°C for five minutes, followed 
by 25 cycles of denaturation at 94°C for 30 s, annealing at 
56°C for 30 s, elongation at 72°C for 45 s, followed by a 
Resistance  Forward sequence Reverse sequence Amplicon size 
genes         (bp)
AdeA AAAATTTT*CTCTAGCCGATGTCGCTCAA AAAATTTT*ATACCTGAGGCTCGCCACTG 510
AdeB AAAATTTT*ACCGCGCTAACTTAGGTATGC AAAATTTT*TCTGAACTTGCACCTGAGGCA 931
AdeC AAAATTTT*TGCGGCAGGTTAGCCCATCG AAAATTTT*GCGGAACAGGATGACCTGCT 435
AdeR AAAATTTT*GACTACGATATTGGCGACAT AAAATTTT*ACGGTTCGCTCTAGTGCATC 560
AdeS AAAATTTT*GATTGGCATGCGCCTCGCAA AAAATTTT*GCCTGCATGTGAATAGCGTA 580
* CCCGGG (SmaI restriction site added to the primer sequences)
Table I. Primer sequences of the adeABC, and adeRS genes.
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final extension step at 72°C for seven minutes.
 The involvement of adeA, adeB, adeC, adeR and 
adeS genes in carbapenem resistance in Acinetobacter 
spp. was performed according to the modified method of 
Héritier et al.(16) Briefly, plasmid pAT801, which confers 
resistance to ampicillin, was used as a shuttle vector. This 
vector is able to replicate in Acinetobacter baumannii and 
Escherichia coli, and it consists of part of the pWH1266 
and pUC18 vectors.(17) Inactivation of blaTEM-1 resistance 
gene of pAT801 was performed as described previously 
by Héritier et al,(16) giving rise to plasmid pAT801-RA, 
conferring resistance to rifampin. An internal fragment to 
the adeA, adeB, adeC, adeR, and adeS genes was amplified 
using primer pairs as listed in Table I. Each PCR product 
was cloned into the Sma1 digested pAT801-RA vector 
individually and electrotransformed into another strain of 
Acinetobacter spp. harbouring the respective ade genes 
in order to disrupt the ade gene sequence and hence to 
study its function. The transformants were selected on 
ticarcillin (50 μg/ml) and rifampin (25 μg/ml) containing 
plates. The successful disruption of adeA, adeB, adeC, 
adeR and adeS genes individually was screened by M13 
primers and primers specific to the inserts. The derivative 
mutants were then subjected to antimicrobial susceptibility 
testing using various antibiotics, including imipenem, 
meropenem, ceftazidime, cefotaxime, gentamicin, 
amikacin, ciprofloxacin and amoxicillin.     
RESULTS
Using the API20NE system for species identification, all 
the strains were detected as Acinetobacter baumannii-
calcoaceticus complex. Growing the strains at 44°C 
showed that among the 39 imipenem-resistant strains, 
36 were Acinetobacter baumannii and only three 
were Acinetobacter calcoaceticus.(10) Further species 
confirmation was done by ARDRA (results not shown). 
All the strains were multiresistant to all the antimicrobials 
tested including imipenem and meropenem. The positive 
strains for blaOXA-23 gene were detected by PCR which 
resulted in the amplicon of size 1058 bp. Among the 39 
carbapenem-resistant strains, 37 were detected positive 
for the presence of this gene. This PCR product of 1058 
bp was sequenced and the data showed that this gene has 
96% amino acid sequence homology to blaOXA-23.
 PCR amplification of AdeABC and AdeRS showed 
that 36 were positive for the presence of adeA, adeB, adeR 
and adeS genes and 34 strains carried adeC gene. In this 
study, the three representative Acinetobacter baumannii 
strains, strain 1, strain 15 and strain 63, were chosen and 
further analysed on the gene association with resistance 
in these strains. Strain 15 and strain 63 harboured all the 
five ade genes whereas strain 1 harboured all the genes 
except the adeC gene. Upon disruption of each ade gene 
by the insertion-inactivation method, the resulting mutants 
were determined for antimicrobial susceptibility testing 
using various antibiotics. Comparing the MIC values of 
the wild-type strains of strain 1, strain 15 and strain 63, 
the derivative mutants showed lower MIC values than its 
parent strains. The MIC values for all the mutants ranged 
from one- to six-fold lower for ceftazidime, cefotaxime, 
gentamicin, amikacin, ciprofloxacin, amoxicillin and 
meropenem, as shown in Table II. The gene knockout 
Strain* IMP (mg/ml) MEM (mg/ml) CAZ (mg/ml) CTX (mg/ml) CN(mg/ml) AK (mg/ml) CIP (mg/ml) AMP (mg/ml)
1 (wild type) 0.032 0.064 0.008 0.064 0.016 0.004 0.008 > 0.512
 1adeA− 0.032 0.032 0.004 0.032 0.008 0.002 0.004 0.512
 1adeB− 0.032 0.016 0.004 0.004 0.002 0.000125 0.00025 0.512
 1adeR− 0.032 0.016 0.004 0.002 0.002 0.00025 0.000125 0.512
 1adeS− 0.032 0.016 0.004 0.004 0.001 0.00025 0.000125 0.512
15 (wild ype) 0.032 0.064 > 0.512 0.032 0.128 0.008 0.064 > 0.512
 15adeA− 0.032 0.032 0.256 0.016 0.064 0.004 0.032 0.256
 15adeB− 0.032 0.016 0.256 0.002 0.016 0.0005 0.004 0.256
 15adeC− 0.032 0.064 0.256 0.064 > 0.512 0.008 0.064 0.256
 15adeR− 0.032 0.016 0.256 0.002 0.032 0.001 0.002 0.256
 15adeS− 0.032 0.016 0.256 0.002 0.032 0.001 0.002 0.256
63 (wild type) 0.016 0.032 > 0.512 0.064 0.128 0.004 0.032 > 0.512
 63adeA− 0.016 0.016 0.256 0.032 0.064 0.002 0.016 0.256
 63adeB− 0.016 0.008 0.256 0.002 0.008 0.00025 0.002 0.256
 63adeC− 0.016 0.032 0.256 0.064 0.512 0.008 0.064 0.256
 63adeR− 0.016 0.008 0.256 0.002 0.032 0.001 0.002 0.256
 63adeS− 0.016 0.008 0.256 0.002 0.032 0.001 0.002 0.256
* The minus (−) sign shows created mutants lacking the respective genes.  
IMP: imipenem; MEM: meropenem; CAZ: ceftazidime; CTX: cefotaxime; CN: gentamicin; AK: amikacin; CIP: ciprofloxacin; AMP: 
ampicillin.
CLSI breakpoints: IMP, MEM and CN (S ≤ 4; I = 8; R ≥ 16); CAZ and AMP (S ≤ 8; I = 16; R ≥32); CTX (S ≤ 8; I = 16-32; R ≥64); AK (S 
≤ 16; I = 32; R ≥64); CIP (S ≤ 1; I = 2; R ≥4). 
Table II. Minimum inhibitory concentrations of β-lactams for three Acinetobacter baumannii strains and its mutants.
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studies showed that the decrease in the MICAK, MICCN, 
MICCIP, and MICCTX is greater in the mutant knockouts 
of the adeB gene as compared to adeA gene. Mutants for 
adeB gene showed a four- to six-fold decrease in MICs as 
compared to adeA gene, which only showed a one-fold 
decrease in MICs compared to that of the wild strain. 
Similar results were observed in gene knockouts of adeR 
gene and adeS gene. The MICMEM in each mutant knockout 
of the adeB gene, adeR gene and adeS gene, respectively, 
showed a two-fold decrease in MICs and only one-fold 
decrease in MICCAZ, and MICAMX. However, all the mutants 
showed no differences in the MIC values for imipenem as 
compared to the wild-type strains.
DISCUSSIOn 
Carbapenem resistance is an emerging problem in 
Acinetobacter spp. worldwide, and is said to be attributed 
to various causes, such as the presence of metallo-
β-lactamases, oxacillinases, and reduced expression 
of OMPs.(4,5) In our study, we report that besides the 
involvement of blaOXA-23 oxacillinases gene, the RND-type 
efflux pump also contributes to carbapenem resistance in 
Acinetobacter spp.  Generally, the presence of β-lactamases 
confer  resistance to β-lactam antibiotics  as they are capable 
of hydrolysing the four members of β-lactam antibiotics 
including penicillins, cephalosporins, monobactam and 
carbapenems. β-lactamases can be divided into four classes 
(A, B, C and D) according to their sequence similarities.(18) 
Based on their different catalytic mechanisms, two groups 
have been established, where the Class B enzymes are 
metallo-β-lactamases that require zinc for their activity, 
while the Class A, C, and D β-lactamases contain serine 
groups in their active site.(19) Oxacillinases are Ambler 
class D β-lactamases with hydrolytic activity against 
penicillins, extended-spectrum cephalosporins, methicillin, 
and aztreonam.(20) However, most of the new OXA-type 
carbapenemases lack hydrolytic activity against oxacillin, 
cloxacillin and methicillin, but they display resistance to 
carbapenems.(15,20) 
 In our samples, 37 of the 39 carbapenem-resistant 
strains were positive for blaOXA-23 gene. This gene was first 
demonstrated by Brown and Amyes from a clinical isolate of 
Acinetobacter baumannii from Scotland.(21) Since then, the 
enzyme has been discovered in England, Brazil, Polynesia, 
Singapore, Korea and China.(21,22) Besides that, other types 
of oxacillinases with carbapenemase activity have been also 
identified in different parts of the world, such as OXA-24 to 
-27, OXA-40, and OXA-58 genes. (5,23-26) In addition to these 
genes, the naturally-occurring oxacillinases such as OXA-
51/-69 have also been studied in detail to elucidate their 
carbapenemase activities in Acinetobacter baumannii.(16,25) 
 The main aim of this study was to characterise the 
AdeABC efflux pump genes together with the two 
component-regulatory genes, AdeRS, and to study their 
contribution to carbapenem resistance in three selected 
Acinetobacter baumannii isolates. All strains had the adeA, 
adeB, adeR, and adeS genes, but only 34 had the adeC 
gene. Disruption of the ade gene resulted in lower MIC 
values than the parent strains for ceftazidime, cefotaxime, 
gentamicin, amikacin, ciprofloxacin, amoxicillin and 
meropenem (Table II). Knocking the gene out showed 
that the decrease in the MICs was greater in the mutants 
lacking adeB gene, adeR gene and adeS gene, while all 
the mutants showed no differences in the MIC values 
for imipenem as compared to the wild-type strains. This 
shows that the efflux pump has an effect on the resistance 
to meropenem compared to imipenem, and the resistance 
may be due to meropenem upregulating the efflux pump, 
as suggested by Livermore.(27) Besides that, among the 
mutants derived from gene knockout of adeA, adeB, adeC, 
adeR and adeS, only mutants derived from adeC resulted 
in a similar resistance to antimicrobial agents tested to 
that of wild-type strains. This indicates that the adeC gene 
was not responsible for the antimicrobial resistance to 
these antibiotics. Therefore, this finding suggests that the 
AdeAB pump may also be utilising other proteins, such as 
the OMP, as suggested by Marchand et al.(8)         
 Reports from other studies had also shown that 
the efflux pumps were responsible for a wide range of 
antibiotic resistance in Gram-negative bacteria.(6,8,15,16) A 
report by Magnet et al has shown that the AdeABC efflux 
pump contributes to multidrug resistance in Acinetobacter 
baumannii including fluoroquinolones, tetracyclines, 
chlorampenicol, erythromycin, trimethoprim and 
ethidium bromide.(6)  However, there is still a scarcity of 
information on efflux-mediated carbapenem resistance 
in the Acinetobacter spp. Recently, Sinha and Srinivasa 
reported the efflux pump as a possible cause for 
carbapenem resistance.(28)  In this study, only nine isolates 
in total were screened, and a comparison of MIC assays 
were demonstrated using reserpine as an efflux pump 
mechanism. It is recommended that screening of more 
isolates are required in order to conclude that the efflux 
pump has a role in carbapenem resistance. To date, the 
study conducted by Sinha and Srinivasa is the only most 
recent publication that has discussed the role of efflux 
pumps in the development of carbapenem resistance in 
Acinetobacters spp (28) 
 In conclusion, our study has shown that besides the 
involvement of blaOXA-23 gene, the three component system, 
AdeABC, and the two-component regulatory system 
AdeRS, have also contributed to carbapenem resistance 
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in Acinetobacter spp. Therefore, it might be crucial to 
understand the carbapenem-resistant mechanisms for 
the development of novel therapeutic strategies, since 
there are multiple mechanisms which affect carbapenem 
resistance in Acinetobacter spp. A novel approach would 
be to attempt to develop efflux inhibitors as a possible 
development of new agents to control antimicrobial 
resistance in nosocomial pathogens, such as Acinetobacter 
spp.  
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